#patientengagement #patientexperience #clinicaltrials #patientjourney #regulatorycompliance #patientcentricity #patientvoice #qualitativeresearch #patientfocus

Patient preferences as input to medical product decision making

PREFER’s patient input to decision making under evaluation by EMA and EUnetHTA. At Clinigma®, we are always happy to follow the development of project...

Laura Lassen Laura Lassen
Have you considered improving the feedback from investigators and study nurses in your clinical trials?

The importance of interviewing investigators and study nurses. Not only is it relevant to interview the patients participating in clinical trials ...

Laura Lassen Laura Lassen
The benefits of interviewing patients when developing orphan drugs

Screening and exit interviews are particularly beneficial to inform the development of drugs for rare diseases. Interviewing patients can be helpful t...

Laura Lassen Laura Lassen
Patient-focused insights - delivered directly to your inbox
Sign up for our newsletter
Can you set a strong outcomes strategy without listening to the patients?

Interviewing patients can help you in choosing the most relevant patient-reported outcome measures to apply in your clinical trials.

Laura Lassen Laura Lassen
CTA-vertical-home
Can you set a strong marketing strategy without hearing what users think about your investigational drug?

Get a clearer picture of your investigational drug prior to market launch. Interestingly, the pharmaceutical industry has remained one of the few ...

Laura Lassen Laura Lassen
EMA wants to strengthen the collaboration with HTAs to reinforce patient relevance in evidence generation

Highlights on EMA’s focus to advance patient-centred access to medicines in partnership with healthcare systems. In EMA’s Regulatory Science Strategy...

Laura Lassen Laura Lassen
Patient-centred drug development in EMA's Regulatory Science Strategy to 2025

As part of the EMA’s Regulatory Science Strategy to 2025, EMA proposes five strategic goals for human medicines regulation. Especially one of these fi...

Laura Lassen Laura Lassen
Are you developing drugs in accordance with regulatory guidances on Patient-Focused Drug Development?

The FDA and the EMA are strengthening Patient-Focused Drug Development. The US Food and Drug Administration (FDA) and the European Medicines Agency (E...

Laura Lassen Laura Lassen
Why PROMs do not guarantee a full picture of patients’ experiences with new drugs

Traditional PROMs (consisting of closed-end questions) have for many years been applied to reveal the patients’ experiences of effects that you expect...

Laura Lassen Laura Lassen
Can you afford to launch a new drug without hearing what patients think about it?

To ensure that you get a clearer picture of a new drug, we recommend interviewing users exposed to a drug candidate as early as possible in the trial...

Laura Lassen Laura Lassen
Introducing the Clinigma® Portal

An IT portal facilitating secure and easy collection of trial patient feedback.

Laura Lassen Laura Lassen
See more stories